AstraZeneca PLC: US Court Dismisses FDA Lawsuit, Firm Evaluating Options

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that on March 23, 2012 the US District Court for the District of Columbia issued an opinion and order in AstraZeneca’s lawsuit against the US Food and Drug Administration (FDA) regarding final marketing approval of generic quetiapine. The Court denied the Company’s request for a preliminary injunction and dismissed the lawsuit without prejudice.

Notwithstanding the Court’s decision, the Company continues to believe strongly in the merits of its position and is evaluating its options.

About the lawsuit and the Citizen Petitions

On March 12, 2012, AstraZeneca filed a lawsuit against the FDA to overturn the FDA’s denial on March 7, 2012 of the Company’s Citizen Petitions with regard to SEROQUEL® (quetiapine fumarate) tablets and SEROQUEL XR® (quetiapine fumarate) extended release tablets.

In its lawsuit AstraZeneca sought an injunction barring the FDA from granting final marketing approval of generic quetiapine until December 2, 2012 when regulatory exclusivity expires on important clinical trial data, or, alternatively, at least until a federal court had a meaningful opportunity to review imminent FDA action regarding the pending generic marketing applications.

On September 9, 2011 AstraZeneca filed a Citizen Petition with the FDA for each of SEROQUEL and SEROQUEL XR, requesting the FDA withhold finally approving any generic quetiapine product that omits from its labeling certain warning language that FDA required AstraZeneca to include in the labeling for SEROQUEL and SEROQUEL XR. Data associated with the warning language at issue is protected by marketing exclusivity periods expiring as late as December 2, 2012. In the Citizen Petitions, AstraZeneca raised important issues regarding labeling requirements for generic copies of innovative medicines, as well as data exclusivity rights granted to innovative companies that conduct new clinical trials.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the US or our AZ&Me Prescription Savings Programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

Contact:

AstraZeneca

Media Enquiries US

Tony Jewell, +1-302-885-4594

or

Julia Walker, +1-302-885-5172

or

Media Enquiries

Esra Erkal-Paler, +44 20 7604 8030

or

Sarah Lindgreen +44, 20 7604 8033

or

Investor Enquiries UK

James Ward-Lilley, +44 20 7604 8122

Mobile: +44 7785 432613

or

Karl Hård, +44 20 7604 8123

Mobile: +44 7789 654364

or

Nicklas Westerholm, +44 20 7604 8124

Mobile: +44 7585 404950

or

Investor Enquiries US

Ed Seage, +1-302-886-4065

Mobile: +1-302-373-1361

or

Jorgen Winroth, +1-212-579-0506

Mobile: +1-917-612-4043

Back to news